Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744850 | 1.00 | KDM1A (0.53) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL2485906 | 0.83 | KDM1A (0.55) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL2485905 | 0.83 | KDM1A (0.55) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL748633 | 0.82 | KDM1A (0.46) | KDM1ACHRNA7KCNH2CA12ENPP1 | |
| SCHEMBL745762 | 0.82 | CHRNA7 (0.53) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL745763 | 0.82 | CHRNA7 (0.53) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL745007 | 0.81 | CHRNA7 (0.53) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL1110495 | 0.81 | CHRNA7 (0.46) | KDM1ACHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL2484828 | 0.81 | CHRNA7 (0.49) | CHRNA7KCNH2SLC6A2SLC6A3 | |
| SCHEMBL2484827 | 0.81 | CHRNA7 (0.49) | CHRNA7KCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | claimed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | claimed |
| US-8940762-B2 | Methods for treating pain | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | disclosed |
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110178121-A1 | Methods for Treating Pain | ABBOTT LABORATORIES (US) | 2011-07-21 | — | — | US | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2018380-A2 | CNS ACTIVE FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | Abbott Laboratories (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2007137030-A2 | CNS ACTIVE FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | KDM1A 2761/4885CHRNA7 2776/4885KCNH2 708/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | KDM1A 2761/4885CHRNA7 2776/4885KCNH2 708/4885 |
| US-20110178121-A1 | Methods for Treating Pain | CHRNA7, CHRNA3, CHRNA5 | KDM1A 2173/4885CHRNA7 1/4885KCNH2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.